STOCKSCREENR
Log In

OBI.L

LSE

Ondine Biomedical Inc.

$11.00+0.00(+0.00%)Mkt Cap: $47.11M

Key Stats

Market Cap

$47.11M

P/E Ratio

-2.75

EPS

$-0.04

Dividend Yield

0.00%

52-Week Range

$7.50 — $18.50

Volume

110.65K

Avg Volume

202.48K

Beta

0.32

Valuation

P/E (TTM)

-2.75

Forward P/E

—

PEG Ratio

-0.03

P/S (TTM)

38.87

P/B (TTM)

7.42

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-4.26%

ROA (TTM)

-1.49%

ROIC

—

Gross Margin

0.64%

Operating Margin

-9.49%

Net Margin

—

Debt/Equity

0.02

Current Ratio

2.05

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.31%

EPS Growth (5Y)

-0.27%

Sales Growth (3Y)

+0.28%

Sales Growth (5Y)

+0.83%

EPS Est (This Year)

$-0.04

EPS Est (Next Year)

$-0.01

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$0.04

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

428.31M

Float

241.94M

Free Float %

56.49%

About

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

LSE

IPO Date

2021-12-06

Employees

18

CEO

Carolyn Cross

Index Membership

—

Website

https://www.ondinebio.com

Ondine Biomedical Inc. (OBI.L) is a healthcare company in the biotechnology industry listed on the LSE. With a market capitalization of $47.11M, a P/E ratio of -2.75, OBI.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare OBI.L against other stocks using dozens of fundamental and technical filters.

Similar Stocks

IMMP

Immutep Limited

$0.41

-12.96%

$59.61M

OABI

OmniAb, Inc.

$1.83

+0.00%

$208.29M

CGEN

Compugen Ltd.

$2.27

+0.00%

$214.64M

CNTN

Canton Strategic Holdings Inc

$3.95

-2.47%

$156.14M

AARD

Aardvark Therapeutics, Inc. Common Stock

$5.33

-0.56%

$116.05M

ONCY

Oncolytics Biotech Inc.

$0.99

-0.92%

$99.44M

Frequently Asked Questions

What is Ondine Biomedical Inc.'s P/E ratio?

Ondine Biomedical Inc. (OBI.L) has a trailing twelve-month (TTM) P/E ratio of -2.75. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Ondine Biomedical Inc. pay a dividend?

No, Ondine Biomedical Inc. (OBI.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Ondine Biomedical Inc.'s market cap?

Ondine Biomedical Inc. (OBI.L) has a market capitalization of $47.11 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.